Sentien Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced that it has opened enrollment in its Phase 1/2 trial of SBI-101 for adult patients with acute kidney injury (AKI). This trial is Sentien’s first clinical program.  Read more here.